top of page


Understanding Interstitial Pneumonia in COVID-19 and Inhibition of CTGF

Recent data indicate the presence of interstitial pneumonia in the majority of hospitalized patients infected with COVID-19. The interstitial pneumonia is usually bilateral and leads to decreased blood oxygen levels, respiratory failure, intubation, and, ultimately, death in a significant proportion of patients who require mechanical ventilation. Connective tissue growth factor (CTGF) may promote vascular leakage and lead to pulmonary edema. Administration of pamrevlumab, an anti-CTGF monoclonal antibody, may mitigate or reverse this edema, and thus improve oxygenation in patients with COVID-19-induced pneumonia. The Italy and U.S. trials will determine if pamrevlumab treatment of hospitalized COVID-19 patients, both during the acute phase of infection and longer term with improved outcomes in interstitial lung fibrosis.

Explore Our Pipeline

We are developing  products with the potential to change lives.

bottom of page